Last update 22 Dec 2024

123-I MNI-340

Overview

Basic Info

Drug Type
Chemical drugs, Diagnostic radiopharmaceuticals
Synonyms-
Target
APP
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors), SPECT(Single-photon emission-computed tomography enhancers)
Therapeutic Areas
Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication-
Inactive Indication
Alzheimer DiseaseAlzheimer Disease, Familial, Type 3Cognitive Dysfunction+ [3]
Originator Organization
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
Active Organization-
Inactive Organization
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with 123-I MNI-340
NCT00968097 / TerminatedPhase 1IIT
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
100 Clinical Results associated with 123-I MNI-340
Login to view more data
100 Translational Medicine associated with 123-I MNI-340
Login to view more data
100 Patents (Medical) associated with 123-I MNI-340
Login to view more data
100 Deals associated with 123-I MNI-340
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer Disease, Familial, Type 3Phase 1
US
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
30 Apr 2008
Cognitive DysfunctionPhase 1
US
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
30 Apr 2008
Dental PlaquePhase 1
US
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
30 Apr 2008
Nervous System MalformationsPhase 1
US
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
30 Apr 2008
Parkinson DiseasePhase 1
US
Institute for Neurodegenerative DisordersInstitute for Neurodegenerative Disorders
30 Apr 2008
Alzheimer DiseasePhase 1
US
-01 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free